Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Gilead Sciences Inc (GILD)

Gilead Sciences Inc (GILD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 79,385,928
  • Shares Outstanding, K 1,253,528
  • Annual Sales, $ 22,449 M
  • Annual Income, $ 5,386 M
  • 60-Month Beta 0.51
  • Price/Sales 3.45
  • Price/Cash Flow 8.55
  • Price/Book 4.48
Trade GILD with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate 1.98
  • Number of Estimates 11
  • High Estimate 2.25
  • Low Estimate 1.64
  • Prior Year 1.10
  • Growth Rate Est. (year over year) +80.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
56.56 +11.97%
on 12/31/20
64.18 -1.32%
on 01/11/21
+3.90 (+6.56%)
since 12/15/20
3-Month
56.56 +11.97%
on 12/31/20
64.18 -1.32%
on 01/11/21
+0.37 (+0.59%)
since 10/15/20
52-Week
56.56 +11.97%
on 12/31/20
85.97 -26.33%
on 03/19/20
-0.77 (-1.20%)
since 01/15/20

Most Recent Stories

More News
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know

Gilead Sciences (GILD) closed at $63.33 in the latest trading session, marking a +1.49% move from the prior day.

GILD : 63.33 (+1.49%)
Gilead Sciences Rises 1.19% on Heavy Volume: Watch For Potential Pullback

Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $62.17 to a high of $63.28. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of...

GILD : 63.33 (+1.49%)
Watch for Gilead Sciences to Potentially Pullback After Gaining 1.19% Yesterday

Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $62.17 to a high of $63.28. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of...

GILD : 63.33 (+1.49%)
Gilead Sciences Set to Possibly Pullback After Yesterday's Rally of 1.19%

Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $62.17 to a high of $63.28. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of...

GILD : 63.33 (+1.49%)
Benchling Doubles Annual Recurring Revenue (ARR) for Fourth Straight Year Amid COVID-19 Pandemic

, /PRNewswire/ -- With biotech seizing headlines amid the COVID-19 pandemic, - the industry's most widely adopted life science R&D cloud - closed another record-breaking year. The company doubled its...

GILD : 63.33 (+1.49%)
Biotech Stock Roundup: Updates From REGN, GILD & VIR, CVAC Teams Up With BAYRY

The biotech sector was in focus last week with guidance updates from quite a few biotechs like Gilead (GILD). Additionally, updates on coronavirus treatments from Regeneron (REGN) and Vir (VIR) were in...

REGN : 517.93 (unch)
GILD : 63.33 (+1.49%)
BLUE : 50.53 (-2.55%)
VIR : 39.31 (+7.73%)
CVAC : 100.35 (-0.24%)
Vir Biotech, Glaxo to Begin Study on Second COVID-19 Therapy

Vir Biotechnology (VIR) and its British partner, Glaxo announces agreement umder which they will evaluate their second coronavirus therapeutic candidate.

GILD : 63.33 (+1.49%)
GSK : 38.47 (+0.81%)
ALNY : 166.36 (+0.78%)
VIR : 39.31 (+7.73%)
3 Biotech Stocks Poised to Outperform Amid Coronavirus Pandemic

3 Biotech Stocks Poised to Outperform Amid Coronavirus Pandemic

VRTX : 225.55 (-0.25%)
REGN : 517.93 (unch)
NVAX : 127.43 (-1.96%)
HALO : 47.43 (+0.81%)
GILD : 63.33 (+1.49%)
BPMC : 100.99 (-1.48%)
BIIB : 275.84 (-1.59%)
Gilead (GILD) Ups Revenue Guidance on Increased Veklury Demand

Gilead (GILD) lifts guidance for 2020, driven by increased Veklury (remdesivir) sales for COVID-19 as the pandemic worsens.

NVO : 72.03 (+1.41%)
GILD : 63.33 (+1.49%)
GSK : 38.47 (+0.81%)
GLPG : 100.01 (-1.68%)
Gilead and Vir Biotechnology Establish Clinical Collaboration to Explore Combination Strategies for Functional Cure for Chronic Hepatitis B Virus

- First Phase 2 clinical trial to combine immunomodulation and antigen suppression approaches in HBV cure research -

GILD : 63.33 (+1.49%)
VIR : 39.31 (+7.73%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products...

See More

Key Turning Points

3rd Resistance Point 65.37
2nd Resistance Point 64.48
1st Resistance Point 63.91
Last Price 63.33
1st Support Level 62.44
2nd Support Level 61.55
3rd Support Level 60.98

See More

52-Week High 85.97
Fibonacci 61.8% 74.74
Fibonacci 50% 71.26
Fibonacci 38.2% 67.79
Last Price 63.33
52-Week Low 56.56

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar